Overview

Buprenorphine Transdermal Patches Pharmacokinetic Study

Status:
Unknown status
Trial end date:
2020-03-31
Target enrollment:
Participant gender:
Summary
This is an open-label, randomised, single-dose, 3 arms study design.
Phase:
Phase 1
Details
Lead Sponsor:
Mundipharma (China) Pharmaceutical Co. Ltd
Treatments:
Buprenorphine
Naltrexone